经动脉灌注利卡汀治疗预防肝细胞癌术后复发

Transarterial Licartin infusion prevents recurrence of hepatocelluar carcinoma

目的 本研究旨在探讨利卡汀在肝细胞癌术后的预防作用.方法 回顾性收集了55例术后行利卡汀治疗的患者为试验组,选取55例未治疗的为对照组,应用多因素的COX回归、生存曲线法及log-rank检验来研究两组预后的差别.结果 经x2检验,两组患者临床参数无差别,而多因素的COX回顾结果表明,利卡汀治疗能够显著降低患者复发（HR,0.604;95％ CI,0.424～0.860,P=0.005）并延长生存时间（HR,0.586;95％ CI 0.358-0.960,P=0.034）,生存曲线也证实此结果.结论：经肝动脉灌注利卡汀治疗能够预防肝细胞癌术后复发并延长生存.此预防作用需随机对照结果予以证实.

Objective This study aimed to investigate the effect of Licartin on prevention of recurrence of hepatocelluar carcinoma （HCC）. Methods Retrospectively collected 55 HCC patients after operation treated by Licartin as,trail group, another 55 patients received none treatment as control group, multivariable COX regression, Kaplan-Meier curve and logrank test were used to assess the difference of prognosis between the two groups. Results Muhivariable COX regression showed that Licartin can significantly decrease the recurrence rate （ FIR, 0. 604 ; 95 % CI, 0. 4244）. 860, P = 0. 005 ） and extend the survival time （ FIR, 0. 586 ; 95 % CI 0. 358 - 0. 960, P = 0. 034） of HCC. Kaplan-Meier curve and log-rank test also showed the same results. Conclusion Transarterial Licartin infusion can prevent recurrence of HCC and extend the survival time. However, the results should be confirmed by random control trail.